{"id":195305,"name":"TAUZIN CONSULTANTS (ON BEHALF OF SORRENTO THERAPEUTICS, INC)","slug":"tauzin-consultants-on-behalf-of-sorrento-therapeutics-inc","state":"LA","country":"United States of America","description":"Government relations, business development, and business incubation firm.","totalSpending":240000,"filings":15,"yearlySpending":[{"year":2019,"income":60000},{"year":2020,"income":120000},{"year":2021,"income":60000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["TAUZIN STRATEGIC NETWORKS"],"lobbyists":["W.J. TAUZIN"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Food & Drug Administration (FDA)"],"sampleDescriptions":["To introduce and discuss the companies products/technologies for medical screening.","Issues related to fair competition, the generic drug market, drug costs, pain management, S.1895, the Lower Health Care Costs Act; Patient Affordability Value and Efficiency Act","Issues related to fair competition, the generic drug market, drug costs, pain management, S.1895, the Lower Health Care Costs Act; Patient Affordability Value and Efficiency Act","Issues related to fair competition, the generic drug market, drug costs, pain management, S.1895, the Lower Health Care Costs Act; Patient Affordability Value and Efficiency Act (bill number TBD).","Drug reimbursement and pricing; non-opioid pain management policies and regulations, and other issues related to health policy."]}